GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PDL BioPharma Inc (NAS:PDLI) » Definitions » Price-to-Free-Cash-Flow

PDL BioPharma (PDL BioPharma) Price-to-Free-Cash-Flow : N/A (As of May. 05, 2024)


View and export this data going back to 1992. Start your Free Trial

What is PDL BioPharma Price-to-Free-Cash-Flow?

As of today (2024-05-05), PDL BioPharma's share price is $2.47. PDL BioPharma's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2020 was $-0.49. Hence, PDL BioPharma's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for PDL BioPharma's Price-to-Free-Cash-Flow or its related term are showing as below:

PDLI's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 31.89
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

PDL BioPharma's Free Cash Flow per Share for the three months ended in Jun. 2020 was $-0.11. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-0.49.


PDL BioPharma Price-to-Free-Cash-Flow Historical Data

The historical data trend for PDL BioPharma's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PDL BioPharma Price-to-Free-Cash-Flow Chart

PDL BioPharma Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.50 2.62 8.98 - -

PDL BioPharma Quarterly Data
Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of PDL BioPharma's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, PDL BioPharma's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PDL BioPharma's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PDL BioPharma's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where PDL BioPharma's Price-to-Free-Cash-Flow falls into.



PDL BioPharma Price-to-Free-Cash-Flow Calculation

PDL BioPharma's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=2.47/-0.487
=N/A

PDL BioPharma's Share Price of today is $2.47.
PDL BioPharma's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.49.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

PDL BioPharma  (NAS:PDLI) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


PDL BioPharma Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of PDL BioPharma's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


PDL BioPharma (PDL BioPharma) Business Description

Traded in Other Exchanges
N/A
Address
932 Southwood Boulevard, Incline Villiage, NV, USA, 89451
PDL BioPharma Inc acquires and manages a portfolio of companies, products, royalty agreements and debt facilities in the biotech, pharmaceutical and medical device industries. The operating segments of the company are Medical Devices, Strategic Positions, Pharmaceutical and Income Generating Assets, of which key revenue is derived from the Pharmaceutical segment. The Pharmaceutical segment consists of revenue derived from branded prescription medicine products sold under the name Tekturna and Tekturna HCT in the U.S, and Rasilez and Rasilez HCT in the rest of the world (collectively, the Noden Products). Geographically, the company operates in Europe, North America, Asia and Other countries, of which prime revenue is generated from Asia and North America.
Executives
David W Gryska director 749 N MARY AVE, SUNNYVALE CA 94085
John Peter Mclaughlin director C/O PDL BIOPHARMA, INC., 932 SOUTHWOOD BOULEVARD, INCLINE VILLAGE NV 89451
Dominique Monnet officer: President and CEO C/O ALEXION PHARMACEUTICALS, INC., 352 KNOTTER DRIVE, CHESHIRE CT 06410
Christopher Lewis Stone officer: VP, Gen. Counsel & Secretary 932 SOUTHWOOD BLVD. INCLINE VILLAGE NV 89451
Alan Lee Bazaar director 9 BEDFORD ROAD, KATONAH NY 10536
Natasha Hernday director 932 SOUTHWOOD BLVD, INCLINE VILLAGE NV 89451
Edward Imbrogno officer: VP Finance, CAO and Acting CFO 932 SOUTHWOOD BLVD. INCLINE VILLAGE NV 89451
Jill M. Jene officer: VP, Business Development 932 SOUTHWOOD BLVD., INCLINE VILLAGE NV 89451
Harold E Selick director
Samuel R Saks director 3180 PORTER DRIVE, PALO ALTO CA 94304
Paul W Sandman director C/O PDL BIOPHARMA, INC., 932 SOUTHWOOD BLVD, INCLINE VILLAGE NV 89451
Shlomo Yanai director ONE MEADOWLANDS PLAZA, EAST RUTHERFORD NJ 07073
Peter S Garcia officer: Vice President, CFO ALX ONCOLOGY HOLDINGS INC., 866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010
Jody S Lindell director 2536 FILLMORE ST., SAN FRANCISCO CA 94115
Paul R Edick director C/O NEWLINK GENETICS CORP., 2503 SOUTH LOOP DR., SUITE 5100, AMES IA 50010